Axis Securities has initiated coverage on Jubilant Ingrevia with a 'BUY' rating and a price target of Rs 705. The brokerage highlights the company's strong performance across its three core segments—Chemical Intermediates, Specialty Chemicals, and Nutrition & Health Solutions—supported by a robust product pipeline of over 100 molecules. With management maintaining its FY27 EBITDA guidance of Rs 750–800 crore, the firm anticipates sequential growth driven by volume and pricing momentum. Investors are advised to watch for project execution and the impact of planned capacity expansions.
Axis Securities Initiates Buy on Jubilant Ingrevia with Rs 705 Target
Jubilant Ingrevia receives a BUY rating from Axis Securities with a target price of Rs 705.
The firm maintains FY27 EBITDA guidance of Rs 750–800 crore citing structural growth.
Reader Takeaway: Strong multi-segment recovery drives the bullish outlook, though raw material price volatility remains a key monitorable risk.
What just happened
Axis Securities has initiated coverage on Jubilant Ingrevia, projecting a 10% upside from the current price of Rs 640. The brokerage points to a broad-based recovery in the company's Chemical Intermediates, Specialty Chemicals, and Nutrition segments as the primary catalyst for the positive outlook.
Why this matters
The company is scaling its high-margin business, supported by a pipeline of over 100 molecules, with 25 already confirmed for commercialization. Furthermore, management expects to achieve Rs 100 crore in operational cost savings by the end of FY27, which is expected to support overall profitability.
Risks to watch
Growth trajectory depends heavily on the timely commissioning of new capacity. The brokerage also flags potential pressure from volatility in energy and raw material prices, which could impact margins if not effectively managed through the company’s pass-through mechanisms.
Context metrics (FY27 Estimates)
Analysts project net sales to reach Rs 5,441 crore for FY27, with an estimated EPS of Rs 23.9. This follows an expected sequential improvement in performance across the firm’s key business units.
What to track next
Investors should monitor the execution of the new plant pipeline and the realization of cost-saving targets. Sustained volume growth in the Specialty Chemicals segment remains a critical metric for long-term valuation.